The presentation is crammed with analysis of the interim results, rationale and design of the DN trial described in yesterday's PR. This conference was the opportunity to correct that weak PR. It did so and much more. It is long winded, but worth listening to. Dr. Schall thoroughly answered the questions I have had since yesterday morning.
No worries. Don't get em wrong, I think their IR has a lot to be desired. And the presentation was very clinical/scientific. Not typically what I like to hear in this setting. But I'm thinking of it as the necessary evil to undo yesterday's blunder. They presented the as-promised interim results in the 3rd Q of 2013. Unfortunately it is exceedingly complex and requires much more than they gave yesterday.
Today's details provide the context for what they are trying to do and what they have seen so far.